Stockreport

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

KalVista Pharmaceuticals, Inc.  (KALV) 
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.kalvista.com
PDF – If approved, sebetralstat will be the first, oral on-demand treatment for HAE –– FDA PDUFA goal date of June 17, 2025 – CAMBRIDGE, Mass. & SALISBURY, England--(BUSI [Read more]